Generation of Airway and Lung Progenitors and Epithelial Cells and Three-Dimensional Anterior Foregut Spheres
US-2015247124-A1 · Sep 3, 2015 · US
Pharmaceutical composition for protecting or mitigating radiation damage, and for preventing or treating pulmonary fibrosis
US2021169882A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2021169882-A1 |
| Application number | US-201816956169-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 20, 2018 |
| Priority date | Dec 20, 2017 |
| Publication date | Jun 10, 2021 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a pharmaceutical composition for inhibiting DNA damage, comprising a GSK3 inhibitor. Further, the present invention provides a pharmaceutical composition for protecting or mitigating radiation against radiation-induced damage, or preventing or treating pulmonary fibrosis, comprising a GSK3 inhibitor.
First claim
Opening claim text (preview).
1 - 7 . (canceled) 8 . A method for inhibiting DNA damage, comprising administering a pharmaceutical composition comprising a GSK3 inhibitor. 9 . A method for protecting or mitigating radiation against radiation-induced damage, comprising administering a pharmaceutical composition comprising a GSK3 inhibitor. 10 . A method for preventing or treating pulmonary fibrosis, comprising administering a pharmaceutical composition comprising a GSK3 inhibitor. 11 . The method of claim 8 , wherein the pharmaceutical composition is administered before, after, or simultaneously with exposure to a DNA damage-inducing factor. 12 . The method of claim 11 , wherein the pharmaceutical composition is administered before exposure to a DNA damage-inducing factor. 13 . The method of claim 9 , wherein the pharmaceutical composition is administered before, after, or simultaneously with exposure to radiation. 14 . The method of claim 10 , wherein the pharmaceutical composition is administered before, after, or simultaneously with exposure to radiation exposure or drug therapy for anticancer treatment. 15 . The method of claim 8 , wherein the GSK3 inhibitor is a compound of Formula 1 or Formula 2 below, or a pharmaceutically acceptable salt or a solvate thereof: 16 . The method of claim 9 , wherein the GSK3 inhibitor is a compound of Formula 1 or Formula 2 below, or a pharmaceutically acceptable salt or a solvate thereof: 17 . The method of claim 10 , wherein the GSK3 inhibitor is a compound of Formula 1 or Formula 2 below, or a pharmaceutically acceptable salt or a solvate thereof: 18 . The method of claim 9 , wherein the radiation-induced damage is at least one selected from vascular damage, skin damage, gastrointestinal tract damage, tissue inflammation, and tissue fibrosis, which are caused by radiation exposure. 19 . The method of claim 10 , wherein the pulmonary fibrosis is induced by radiation exposure or drug therapy for anticancer treatment. 20 . The method of claim 15 , wherein the pharmaceutically acceptable salt is hydrochloride. 21 . The method of claim 16 , wherein the pharmaceutically acceptable salt is hydrochloride. 22 . The method of claim 17 , wherein the pharmaceutically acceptable salt is hydrochloride.
Assignees
Inventors
Classifications
- A61P39/00Primary
General protective or antinoxious agents · CPC title
Drugs for disorders of the respiratory system · CPC title
- A61K31/506Primary
not condensed and containing further heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2021169882A1 cover?
- The present invention provides a pharmaceutical composition for inhibiting DNA damage, comprising a GSK3 inhibitor. Further, the present invention provides a pharmaceutical composition for protecting or mitigating radiation against radiation-induced damage, or preventing or treating pulmonary fibrosis, comprising a GSK3 inhibitor.
- Who is the assignee on this patent?
- Korea Inst Radiological & Medical Sciences
- What technology area does this patent fall under?
- Primary CPC classification A61P39/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Jun 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).